Table 2.

Comparative trials of natural surfactants for respiratory distress syndrome

Trials (7)	Surfactant	N	Prophylaxis (P) or Rescue (Tx)	Patients	Results
Bloom et al.22	Survanta. vs Infasurf.	374	P	<1250 g	No difference in any variables; Infasurf: increased mortality in infants <600 g
Bloom et al.22	Survanta. vs Infasurf.	608	Tx	<2000 g	Infasurf: lower average 0–72 h FiO2 and MAP
Speer et al.23	Survanta. vs Curosurf.	73	Tx	700–1500 g	Curosurf: lower FiO2, PIP, MAP at 12–24 h
Baroutis et al.24	Alveofact. vs Survanta. vs Curosurf.	80	Tx	<2000 g	Curosurf: fewer days on O2 & mechanical ventilation, decreased length of stay
Ramanathan et al.25	Survanta. vs Curosurf.	293	Tx		Curosurf: faster weaning, fewer doses, decreased mortality, cost effective
Malloy et al.26	Survanta. vs Curosurf.	58	Tx		Curosurf: lower FiO2 up to 48 h, fewer doses
Bloom and Clark27	Survanta. vs Infasurf.	749a	P	<30 weeks	No definite conclusions
Bloom and Clark27	Survanta. vs Infasurf.	1361a	Tx	401–2000 g	No definite conclusions

Abbreviations: MAP, mean airway pressure; PIP, peak inspiratory pressure.

^aTrial stopped due to slow enrollment.

Copyright 2000 from Lung Surfactants: Basic Science and Clinical Applications by Notter RH. Adapted by permission of Routledge/Taylor & Francis Group, LLC.²¹